Chartwell Pennsylvania, LP is First Pennsylvania Specialty Pharmacy Accredited with Distinction in Oncology
According to ACHC, this oncology accreditation includes the recognition of delivery of medications for the treatment of cancer-specific conditions; the ability to identify the toxic nature of these medications; and the collaboration between the physician, pharmacist and patient to optimize the patient’s plan of care, cost containment and outcomes.
Peter Ellis, M.D., director of the Medical Oncology Network at UPMC Hillman Cancer Center, applauded Chartwell’s industry-leading oncology program and patient-centric model.
“Chartwell has been a leader in oncology services for many years,” said Ellis. “They always put our patients first, so I am not at all surprised by this distinction from ACHC.”
It is estimated that 25 to 35 percent of all cancer drugs in development are oral agents. Dispensing these oral oncology medications presents several advantages over infused medications—including patient convenience, improved monitoring of compliance and patient side effects, and prompt treatment.
Chartwell President, Kathleen Patrick, credits the achievement on the continuous quality efforts made by staff to ensure a positive experience for all patients.
“Our clinicians and support staff work very hard on behalf of our patients,” said Patrick. “We take great pride in patient satisfaction scores that range between 98 to 100 percent every month. To have earned this distinction is a testament to our staff efforts to ensure our patients receive the care they deserve.”
For more than 25 years, Chartwell has provided many of the latest, most advanced therapies and medications to patients for the treatment of chronic, rare and/or complex conditions. The pharmacy provides services, therapies and medications for both home infusion and specialty pharmacy patients throughout Pennsylvania, West Virginia, Ohio and New York.